Business Context and Reporting Period
This Form 8-K is filed by ARTELO BIOSCIENCES, INC. (Nasdaq: ARTL) with a report date of November 19, 2025. The filing addresses a critical corporate governance and listing status issue regarding the Company's compliance with Nasdaq continued listing requirements.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, or debt figures. The primary financial metric disclosed is the Company's failure to meet the Listing Rule 5550(b)(1) requirement to maintain stockholders' equity of at least $2,500,000. The Company also failed to meet alternative standards regarding market value of listed securities or net income from continuing operations.
Material Changes
- Delisting Determination: On November 19, 2025, the Nasdaq Listing Qualifications Department issued a delist determination letter.
- Plan Failure: The Staff determined that the Company did not complete the capital raising activities outlined in plans submitted on July 7, 2025, and August 29, 2025, which were intended to restore compliance.
- Timeline: Unless an appeal is filed by November 26, 2025, securities are scheduled to be delisted on December 1, 2025.
Outlook, Management Commentary, and Risks
Management Action: The Company intends to appeal the delisting determination to a hearing panel under Nasdaq Listing Rule 5800 Series. This appeal is expected to stay further delisting actions pending the hearing outcome.
Trading Status: Following the appeal request, the Company's common stock will continue to trade on Nasdaq under the symbol "ARTL."
Risks: The primary risk is the potential removal of the Company's securities from the Nasdaq Stock Market if the appeal is unsuccessful or if compliance is not achieved during the appeal process.
Investor Verification Checklist
- Verify the filing of the appeal with the Nasdaq hearing panel by the November 26, 2025 deadline.
- Monitor the status of the Company's stockholders' equity to determine if it has reached the $2,500,000 threshold.
- Review any subsequent filings regarding the outcome of the hearing panel or new capital raising efforts.
- Confirm the continued trading status of "ARTL" on Nasdaq post-appeal.